BR0311627A - Conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteìnas portadoras de ferro e métodos de utilização - Google Patents

Conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteìnas portadoras de ferro e métodos de utilização

Info

Publication number
BR0311627A
BR0311627A BR0311627-1A BR0311627A BR0311627A BR 0311627 A BR0311627 A BR 0311627A BR 0311627 A BR0311627 A BR 0311627A BR 0311627 A BR0311627 A BR 0311627A
Authority
BR
Brazil
Prior art keywords
iron
covalent conjugates
methods
artemisinin
carrying proteins
Prior art date
Application number
BR0311627-1A
Other languages
English (en)
Inventor
Henry C Lai
Tomikazu Sasaki
Narendra P Singh
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Priority claimed from PCT/US2003/017881 external-priority patent/WO2003103592A2/en
Publication of BR0311627A publication Critical patent/BR0311627A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"CONJUGADOS COVALENTES ENTRE ENDOPERóXIDOS ARTEMISININO-RELACIONADOS E PROTEìNAS PORTADORAS DE FERRO E MéTODOS DE UTILIZAçãO". A invenção proporciona conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteínas portadoras de ferro. Em algumas modalidades, os conjugados covalentes compreendem artelinato e holotransferrina. Em um outro aspecto, a invenção proporciona métodos para administrar os conjugados covalentes da invenção para tratar câncer e infecções por patógenos que se ligam a proteínas portadoras de ferro.
BR0311627-1A 2002-06-06 2003-06-06 Conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteìnas portadoras de ferro e métodos de utilização BR0311627A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38692802P 2002-06-06 2002-06-06
PCT/US2003/017881 WO2003103592A2 (en) 2002-06-06 2003-06-06 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use

Publications (1)

Publication Number Publication Date
BR0311627A true BR0311627A (pt) 2005-08-30

Family

ID=29736235

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0312685-4A BR0312685A (pt) 2002-06-06 2003-06-06 Métodos de utilização de compostos do tipo artemisinina para prevenir ou retardar o aparecimento de cancêr
BR0311627-1A BR0311627A (pt) 2002-06-06 2003-06-06 Conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteìnas portadoras de ferro e métodos de utilização

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0312685-4A BR0312685A (pt) 2002-06-06 2003-06-06 Métodos de utilização de compostos do tipo artemisinina para prevenir ou retardar o aparecimento de cancêr

Country Status (11)

Country Link
US (2) US20040058981A1 (pt)
EP (2) EP1531851B1 (pt)
JP (2) JP4440768B2 (pt)
CN (3) CN1668293A (pt)
AU (2) AU2003243418B2 (pt)
BR (2) BR0312685A (pt)
CA (2) CA2488360A1 (pt)
NZ (2) NZ537113A (pt)
RU (2) RU2325156C2 (pt)
WO (1) WO2003103588A2 (pt)
ZA (1) ZA200500023B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515761C (en) * 2003-02-12 2013-04-23 Georgetown University Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7744861B2 (en) * 2003-09-17 2010-06-29 Nektar Therapeutics Multi-arm polymer prodrugs
CN1255106C (zh) * 2003-09-26 2006-05-10 李国桥 复方青蒿素
US20050096369A1 (en) * 2003-11-04 2005-05-05 Hoang Ba X. Compositions and methods for treating cellular proliferation disorders
AU2004290983A1 (en) * 2003-11-19 2005-06-02 Vecta Ltd. Methods and compositions for the treatment of Helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
CN1311832C (zh) * 2005-01-12 2007-04-25 四川科伦药业股份有限公司 溴代二氢青蒿素的医药用途
US20060270863A1 (en) * 2005-05-27 2006-11-30 Amyris Biotechnologies Conversion of amorpha-4,11-diene to artemisinin and artemisinin precursors
KR20140126404A (ko) * 2005-10-20 2014-10-30 에피팜 게엠베하 아르테미시닌 및 그의 유도체를 이용한 양성 착색 점(반점)의 처치 및 예방
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
WO2007112451A2 (en) * 2006-03-28 2007-10-04 University Of Washington Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
WO2008046109A2 (en) * 2006-10-13 2008-04-17 University Of Washington Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
KR101441709B1 (ko) 2006-11-30 2014-09-18 넥타르 테라퓨틱스 중합체 컨쥬게이트의 제조 방법
MX2009008549A (es) * 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
RU2515063C9 (ru) * 2008-01-30 2014-08-10 Пиерис АГ Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека, и способы их получения
CN101323569B (zh) * 2008-07-24 2011-01-26 上海交通大学 倍半萜青蒿萜酯ae及其提取纯化方法
JP5588983B2 (ja) * 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
BRPI0919842A8 (pt) * 2008-10-21 2015-09-22 Enzon Pharmaceuticals Inc tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina
BRPI1014887A8 (pt) * 2009-04-23 2019-02-12 Londonpharma Ltd composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal
GB2469791B (en) * 2009-04-23 2011-12-14 Londonpharma Ltd Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
JP5624735B2 (ja) 2009-07-22 2014-11-12 国立大学法人岡山大学 フィルター
CN102399142B (zh) * 2010-09-14 2014-09-24 华北制药集团新药研究开发有限责任公司 一类倍半萜酯化合物及其制备方法和用途
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
CN102727522B (zh) * 2011-04-08 2013-09-25 石雁羽 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂
CN103845360A (zh) * 2012-11-29 2014-06-11 昆明制药集团股份有限公司 含蒿甲醚的药物组合物、制剂及其用途
CN103405779B (zh) * 2013-07-18 2015-09-30 江苏省血吸虫病防治研究所 一种预防血吸虫感染长效青蒿琥酯药物及其制备方法
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
CN109908137B (zh) * 2019-03-11 2022-02-18 江苏省人民医院（南京医科大学第一附属医院） 青蒿素在杀伤乳腺癌干细胞的药物中的应用
CN114983999A (zh) * 2022-06-09 2022-09-02 四川大学 一种青蒿素及其衍生物的新用途、验证方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US5472684A (en) * 1993-06-02 1995-12-05 Colgate Palmolive Company Oral compositions for plaque and gingivitis
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5677468A (en) * 1995-06-29 1997-10-14 Hauser, Inc. Artemisinin dimer compounds having anticancer activity
US5869310A (en) * 1996-06-03 1999-02-09 Promega Corporation Isolated agarase enzyme from flavobacterium sp. strain NR19, cloned genes therefor, and expression thereof in transformed host cells
US6160004A (en) * 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
CN1084333C (zh) * 1998-06-17 2002-05-08 中国科学院上海药物研究所 新的青蒿素化合物,其制备方法以及含有它们的药物组合物
US6127405A (en) * 1998-07-10 2000-10-03 Council Of Scientific And Industrial Research Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent
US6297272B1 (en) * 1999-01-12 2001-10-02 Hauser, Inc. Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same
IN191696B (pt) * 1999-02-12 2003-12-20 Council Scient Ind Res
GB9916012D0 (en) * 1999-07-09 1999-09-08 Ufc Limited Peroxide-based antimalarial compounds
JP2002128784A (ja) * 2000-10-25 2002-05-09 Japan Science & Technology Corp 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類
WO2002091992A2 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections

Also Published As

Publication number Publication date
US20080119542A1 (en) 2008-05-22
AU2003243418B2 (en) 2009-02-19
CA2488360A1 (en) 2003-12-18
CN1313145C (zh) 2007-05-02
RU2325156C2 (ru) 2008-05-27
NZ537114A (en) 2007-02-23
AU2003251405A1 (en) 2003-12-22
EP1553935A2 (en) 2005-07-20
EP1531851B1 (en) 2011-12-14
CN1668293A (zh) 2005-09-14
RU2004139096A (ru) 2005-06-10
EP1553935A4 (en) 2010-07-07
ZA200500023B (en) 2005-10-20
JP2005529938A (ja) 2005-10-06
BR0312685A (pt) 2005-09-06
NZ537113A (en) 2007-01-26
RU2004139090A (ru) 2005-06-10
JP4440768B2 (ja) 2010-03-24
CN1668323A (zh) 2005-09-14
EP1531851A4 (en) 2007-12-12
WO2003103588A3 (en) 2004-04-15
CN101843904A (zh) 2010-09-29
EP1531851A2 (en) 2005-05-25
WO2003103588A2 (en) 2003-12-18
AU2003243418A1 (en) 2003-12-22
JP2005535606A (ja) 2005-11-24
CA2488347A1 (en) 2003-12-18
US20040058981A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
BR0311627A (pt) Conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteìnas portadoras de ferro e métodos de utilização
BR0112111A (pt) Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
EP2263697A3 (en) Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE478094T1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate,die diese enthalten
EP1383785A4 (en) RECOMBINANT, TUMOR-SPECIFIC ANTIBODIES AND THEIR USE
HK1076055A1 (en) Covalent conjugates between artemisinin-related endoperoxides and iron- carrying proteins and methods of use
GB0507598D0 (en) Composition
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
GB0111628D0 (en) Binding member
SG153877A1 (en) Treatment of cancer
MXPA04006747A (es) Tratamiento de cancer.
TW200635950A (en) Specific binding agents of human angiopoietin-2
TNSN06454A1 (en) Treatment of cancer
CY1115692T1 (el) Επιλεγμενα αντισωματα που δεσμευονται σε αμινοφωσφολιπιδια και η χρηση αυτων στην αγωγη, οπως του καρκινοy
ATE490981T1 (de) Criptospezifische antikörper

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDADA PRIORIDADE REIVINDICADA (US 60/386.928 DE 06/06/02), POR NAO ESTAR EM CONFORMIDADE COM O PREVISTO NOS PARAGRAFOS 6 E 7 DO ARTIGO 16 DA LPI.

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: PUBLICADA NA RPI NO 2014, DE 11/08/2009, POR TER SIDO INDEVIDA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.